

Denosumab Market Outlook 2025-2034: Market Share, and Growth Analysis By Drug Classification (Prolia, Xgeva, Others), By Type (60 mg, 120 mg), By End-Users

<https://marketpublishers.com/r/DD6C35594C10EN.html>

Date: October 2025

Pages: 160

Price: US\$ 3,950.00 (Single User License)

ID: DD6C35594C10EN

Abstracts

The Denosumab Market is valued at USD 4.3 billion in 2025 and is projected to grow at a CAGR of 15.2% to reach USD 15.3 billion by 2034. The Denosumab Market focuses on the pharmaceutical drug denosumab, a monoclonal antibody used to treat various bone-related conditions. It is primarily prescribed for osteoporosis (in postmenopausal women and men at high risk of fracture), bone loss in patients receiving certain cancer treatments, and skeletal-related events (SREs) in patients with bone metastases from solid tumors. Denosumab works by inhibiting the formation of osteoclasts, cells that break down bone, thereby increasing bone density and reducing the risk of fractures and SREs. The market is driven by the increasing prevalence of osteoporosis and bone metastases, as well as the efficacy of denosumab in treating these conditions. The Denosumab Market continued to be a significant segment within the bone health and oncology therapeutics areas. Its established efficacy and convenient subcutaneous administration contributed to its widespread use. Research continued to explore the long-term effects of denosumab and its potential in other bone-related disorders. Biosimilar competition began to emerge in some regions, potentially impacting market dynamics and pricing. The market also saw ongoing efforts to educate patients and healthcare providers about the appropriate use of denosumab. The Denosumab Market is expected to remain robust, although it will likely face increasing competition from biosimilars. The continued aging of the global population and the rising incidence of cancer with bone metastases will sustain demand. Ongoing research may uncover new applications for denosumab or optimize its current use. Market access and reimbursement policies will continue to play a crucial role in its availability. The impact of biosimilars on market share and pricing will be a key factor shaping the future

landscape.

Key Insights Denosumab Market

Increasing biosimilar competition for denosumab in various regions, potentially leading to price erosion and greater patient access.

Continued research into the long-term efficacy and safety profile of denosumab in treating osteoporosis and preventing skeletal-related events.

Exploration of potential new applications for denosumab in other bone-related conditions or in combination with other therapies.

Ongoing efforts to educate healthcare providers and patients on the appropriate use and benefits of denosumab.

Market access and reimbursement policies continuing to influence the availability and uptake of denosumab in different healthcare systems.

The increasing global prevalence of osteoporosis, particularly in postmenopausal women and the elderly, leading to a higher risk of fractures.

The rising incidence of various cancers that can metastasize to the bone, causing skeletal-related events such as fractures, pain, and the need for radiation or surgery.

The proven efficacy of denosumab in increasing bone mineral density and reducing the risk of fractures and skeletal-related events.

The convenient subcutaneous route of administration of denosumab, which can be administered less frequently compared to some other bone-modifying agents.

The potential for adverse effects associated with denosumab, such as hypocalcemia and osteonecrosis of the jaw, requires careful patient selection and monitoring.

Denosumab Market Segmentation

By Drug Classification

Prolia

Xgeva

Others

By Type

60 mg

120 mg

By End-Users

Hospitals

Homecare

Specialty Clinics

Ambulatory Surgical Centers

Key Companies Analysed

Johnson & Johnson

F. Hoffmann-La Roche Ltd.

Novartis International AG

Sanofi SA

GlaxoSmithKline plc

Eli Lilly and Company

Amgen Inc.

Asahi Kasei Corporation

Teva Pharmaceutical Industries Ltd.

Astellas Pharma Inc.

Daiichi Sankyo Company

Limited

Mylan N.V.

Sandoz International GmbH

Daiichi Sankyo Company Limited

Aurobindo Pharma Limited

Cipla Limited

Dr. Reddy's Laboratories Ltd.

Hikma Pharmaceuticals PLC

Celltrion Inc.

Amneal Pharmaceuticals Inc

Cadila Healthcare Limited

Lupin Limited

Biocon Limited

Torrent Pharmaceuticals Ltd.

Jubilant Life Sciences Limited

Ajanta Pharma Limited

Denosumab Market Analytics

The report employs rigorous tools, including Porter's Five Forces, value chain mapping, and scenario-based modeling, to assess supply–demand dynamics. Cross-sector influences from parent, derived, and substitute markets are evaluated to identify risks and opportunities. Trade and pricing analytics provide an up-to-date view of international flows, including leading exporters, importers, and regional price trends.

Macroeconomic indicators, policy frameworks such as carbon pricing and energy security strategies, and evolving consumer behavior are considered in forecasting scenarios. Recent deal flows, partnerships, and technology innovations are incorporated to assess their impact on future market performance.

Denosumab Market Competitive Intelligence

The competitive landscape is mapped through OG Analysis' proprietary frameworks, profiling leading companies with details on business models, product portfolios, financial performance, and strategic initiatives. Key developments such as mergers & acquisitions, technology collaborations, investment inflows, and regional expansions are analyzed for their competitive impact. The report also identifies emerging players and innovative startups contributing to market disruption.

Regional insights highlight the most promising investment destinations, regulatory landscapes, and evolving partnerships across energy and industrial corridors.

Countries Covered

North America — Denosumab market data and outlook to 2034

United States

Canada

Mexico

Europe — Denosumab market data and outlook to 2034

Germany

United Kingdom

France

Italy

Spain

BeNeLux

Russia

Sweden

Asia-Pacific — Denosumab market data and outlook to 2034

China

Japan

India

South Korea

Australia

Indonesia

Malaysia

Vietnam

Middle East and Africa — Denosumab market data and outlook to 2034

Saudi Arabia

South Africa

Iran

UAE

Egypt

South and Central America — Denosumab market data and outlook to 2034

Brazil

Argentina

Chile

Peru

** We can include data and analysis of additional countries on demand.*

Research Methodology

This study combines primary inputs from industry experts across the Denosumab value chain with secondary data from associations, government publications, trade databases, and company disclosures. Proprietary modeling techniques, including data triangulation, statistical correlation, and scenario planning, are applied to deliver reliable market sizing and forecasting.

Key Questions Addressed

What is the current and forecast market size of the Denosumab industry at global, regional, and country levels?

Which types, applications, and technologies present the highest growth potential?

How are supply chains adapting to geopolitical and economic shocks?

What role do policy frameworks, trade flows, and sustainability targets play in shaping demand?

Who are the leading players, and how are their strategies evolving in the face of global uncertainty?

Which regional “hotspots” and customer segments will outpace the market, and what go-to-market and partnership models best support entry and expansion?

Where are the most investable opportunities—across technology roadmaps, sustainability-linked innovation, and M&A—and what is the best segment to invest over the next 3–5 years?

Your Key Takeaways from the Denosumab Market Report

Global Denosumab market size and growth projections (CAGR), 2024-2034

Impact of Russia-Ukraine, Israel-Palestine, and Hamas conflicts on Denosumab trade, costs, and supply chains

Denosumab market size, share, and outlook across 5 regions and 27 countries, 2023-2034

Denosumab market size, CAGR, and market share of key products, applications, and end-user verticals, 2023-2034

Short- and long-term Denosumab market trends, drivers, restraints, and opportunities

Porter’s Five Forces analysis, technological developments, and Denosumab supply chain analysis

Denosumab trade analysis, Denosumab market price analysis, and Denosumab supply/demand dynamics

Profiles of 5 leading companies—overview, key strategies, financials, and products

Latest Denosumab market news and developments

Additional Support

With the purchase of this report, you will receive

An updated PDF report and an MS Excel data workbook containing all market tables and figures for easy analysis.

7-day post-sale analyst support for clarifications and in-scope supplementary data, ensuring the deliverable aligns precisely with your requirements.

Complimentary report update to incorporate the latest available data and the impact of recent market developments.

** The updated report will be delivered within 3 working days*

Contents

1. TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

2. GLOBAL DENOSUMAB MARKET SUMMARY, 2025

- 2.1 Denosumab Industry Overview
 - 2.1.1 Global Denosumab Market Revenues (In US\$ billion)
- 2.2 Denosumab Market Scope
- 2.3 Research Methodology

3. DENOSUMAB MARKET INSIGHTS, 2024-2034

- 3.1 Denosumab Market Drivers
- 3.2 Denosumab Market Restraints
- 3.3 Denosumab Market Opportunities
- 3.4 Denosumab Market Challenges
- 3.5 Tariff Impact on Global Denosumab Supply Chain Patterns

4. DENOSUMAB MARKET ANALYTICS

- 4.1 Denosumab Market Size and Share, Key Products, 2025 Vs 2034
- 4.2 Denosumab Market Size and Share, Dominant Applications, 2025 Vs 2034
- 4.3 Denosumab Market Size and Share, Leading End Uses, 2025 Vs 2034
- 4.4 Denosumab Market Size and Share, High Growth Countries, 2025 Vs 2034
- 4.5 Five Forces Analysis for Global Denosumab Market
 - 4.5.1 Denosumab Industry Attractiveness Index, 2025
 - 4.5.2 Denosumab Supplier Intelligence
 - 4.5.3 Denosumab Buyer Intelligence
 - 4.5.4 Denosumab Competition Intelligence
 - 4.5.5 Denosumab Product Alternatives and Substitutes Intelligence
 - 4.5.6 Denosumab Market Entry Intelligence

5. GLOBAL DENOSUMAB MARKET STATISTICS – INDUSTRY REVENUE, MARKET SHARE, GROWTH TRENDS AND FORECAST BY SEGMENTS, TO 2034

5.1 World Denosumab Market Size, Potential and Growth Outlook, 2024- 2034 (\$ billion)

5.1 Global Denosumab Sales Outlook and CAGR Growth By Drug Classification, 2024-2034 (\$ billion)

5.2 Global Denosumab Sales Outlook and CAGR Growth By Type, 2024- 2034 (\$ billion)

5.3 Global Denosumab Sales Outlook and CAGR Growth By End-Users, 2024- 2034 (\$ billion)

5.4 Global Denosumab Market Sales Outlook and Growth by Region, 2024- 2034 (\$ billion)

6. ASIA PACIFIC DENOSUMAB INDUSTRY STATISTICS – MARKET SIZE, SHARE, COMPETITION AND OUTLOOK

6.1 Asia Pacific Denosumab Market Insights, 2025

6.2 Asia Pacific Denosumab Market Revenue Forecast By Drug Classification, 2024-2034 (USD billion)

6.3 Asia Pacific Denosumab Market Revenue Forecast By Type, 2024- 2034 (USD billion)

6.4 Asia Pacific Denosumab Market Revenue Forecast By End-Users, 2024- 2034 (USD billion)

6.5 Asia Pacific Denosumab Market Revenue Forecast by Country, 2024- 2034 (USD billion)

6.5.1 China Denosumab Market Size, Opportunities, Growth 2024- 2034

6.5.2 India Denosumab Market Size, Opportunities, Growth 2024- 2034

6.5.3 Japan Denosumab Market Size, Opportunities, Growth 2024- 2034

6.5.4 Australia Denosumab Market Size, Opportunities, Growth 2024- 2034

7. EUROPE DENOSUMAB MARKET DATA, PENETRATION, AND BUSINESS PROSPECTS TO 2034

7.1 Europe Denosumab Market Key Findings, 2025

7.2 Europe Denosumab Market Size and Percentage Breakdown By Drug Classification, 2024- 2034 (USD billion)

7.3 Europe Denosumab Market Size and Percentage Breakdown By Type, 2024- 2034 (USD billion)

7.4 Europe Denosumab Market Size and Percentage Breakdown By End-Users, 2024-2034 (USD billion)

7.5 Europe Denosumab Market Size and Percentage Breakdown by Country, 2024-

2034 (USD billion)

- 7.5.1 Germany Denosumab Market Size, Trends, Growth Outlook to 2034
- 7.5.2 United Kingdom Denosumab Market Size, Trends, Growth Outlook to 2034
- 7.5.2 France Denosumab Market Size, Trends, Growth Outlook to 2034
- 7.5.2 Italy Denosumab Market Size, Trends, Growth Outlook to 2034
- 7.5.2 Spain Denosumab Market Size, Trends, Growth Outlook to 2034

8. NORTH AMERICA DENOSUMAB MARKET SIZE, GROWTH TRENDS, AND FUTURE PROSPECTS TO 2034

- 8.1 North America Snapshot, 2025
- 8.2 North America Denosumab Market Analysis and Outlook By Drug Classification, 2024- 2034 (\$ billion)
- 8.3 North America Denosumab Market Analysis and Outlook By Type, 2024- 2034 (\$ billion)
- 8.4 North America Denosumab Market Analysis and Outlook By End-Users, 2024- 2034 (\$ billion)
- 8.5 North America Denosumab Market Analysis and Outlook by Country, 2024- 2034 (\$ billion)
 - 8.5.1 United States Denosumab Market Size, Share, Growth Trends and Forecast, 2024- 2034
 - 8.5.1 Canada Denosumab Market Size, Share, Growth Trends and Forecast, 2024- 2034
 - 8.5.1 Mexico Denosumab Market Size, Share, Growth Trends and Forecast, 2024- 2034

9. SOUTH AND CENTRAL AMERICA DENOSUMAB MARKET DRIVERS, CHALLENGES, AND FUTURE PROSPECTS

- 9.1 Latin America Denosumab Market Data, 2025
- 9.2 Latin America Denosumab Market Future By Drug Classification, 2024- 2034 (\$ billion)
- 9.3 Latin America Denosumab Market Future By Type, 2024- 2034 (\$ billion)
- 9.4 Latin America Denosumab Market Future By End-Users, 2024- 2034 (\$ billion)
- 9.5 Latin America Denosumab Market Future by Country, 2024- 2034 (\$ billion)
 - 9.5.1 Brazil Denosumab Market Size, Share and Opportunities to 2034
 - 9.5.2 Argentina Denosumab Market Size, Share and Opportunities to 2034

10. MIDDLE EAST AFRICA DENOSUMAB MARKET OUTLOOK AND GROWTH

PROSPECTS

10.1 Middle East Africa Overview, 2025

10.2 Middle East Africa Denosumab Market Statistics By Drug Classification, 2024-2034 (USD billion)

10.3 Middle East Africa Denosumab Market Statistics By Type, 2024- 2034 (USD billion)

10.4 Middle East Africa Denosumab Market Statistics By End-Users, 2024- 2034 (USD billion)

10.5 Middle East Africa Denosumab Market Statistics by Country, 2024- 2034 (USD billion)

10.5.1 Middle East Denosumab Market Value, Trends, Growth Forecasts to 2034

10.5.2 Africa Denosumab Market Value, Trends, Growth Forecasts to 2034

11. DENOSUMAB MARKET STRUCTURE AND COMPETITIVE LANDSCAPE

11.1 Key Companies in Denosumab Industry

11.2 Denosumab Business Overview

11.3 Denosumab Product Portfolio Analysis

11.4 Financial Analysis

11.5 SWOT Analysis

12 APPENDIX

12.1 Global Denosumab Market Volume (Tons)

12.1 Global Denosumab Trade and Price Analysis

12.2 Denosumab Parent Market and Other Relevant Analysis

12.3 Publisher Expertise

12.2 Denosumab Industry Report Sources and Methodology

I would like to order

Product name: Denosumab Market Outlook 2025-2034: Market Share, and Growth Analysis By Drug Classification (Prolia, Xgeva, Others), By Type (60 mg, 120 mg), By End-Users

Product link: <https://marketpublishers.com/r/DD6C35594C10EN.html>

Price: US\$ 3,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/DD6C35594C10EN.html>